Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin + sulfonylurea
- Development stage
- Unknown
- Lead developer
- Arecor Therapeutics
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy approach using both insulin and sulfonylurea medications to manage type 2 diabetes mellitus. Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, while exogenous insulin supplements the body's natural insulin. This combination provides complementary mechanisms to improve glycemic control when monotherapy is insufficient. The combination carries an increased risk of hypoglycemia and requires careful monitoring.
- Other names
- sulfonylurea and insulinsulfonylureas plus insulin
02
Targets
INSR (Insulin receptor)KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on insulin + sulfonylurea.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin + sulfonylurea.